ERBB2 and breast cancer: In view of our data showing the activities of both ADAM10 and ADAM17 in response to trastuzumab, we would support further studies to be done to assess the efficacy of ADAM10/17 inhibitor as a novel therapy to overcome trastuzumab resistance for HER2 positive breast cancer patients.